Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Seyltx gains access to Algernon’s NP-120 (ifenprodil), an N-methyl-D-aspartate receptor antagonist specifically targeting the NMDA type subunit 2B and a novel first-in-class treatment for idiopathic pulmonary fibrosis and its associated cough.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: NP-120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Seyltx
Deal Size: $2.0 million Upfront Cash: $2.0 million
Deal Type: Acquisition March 27, 2024
Details:
AP-188 (N,N-dimethyltryptamine) is a tryptamine, non-selective agonist for 5HT2a receptor and produces hallucinogenic effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin. It is being investigated for ischemic stroke.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Neurology Product Name: AP-188
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2023
Details:
AP-188 (N,N-dimethyltryptamine), is a tryptamine, non-selective agonist for 5HT2a receptor and produces hallucinogenic effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin. It is being investigated for ischemic stroke.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Neurology Product Name: AP-188
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023
Details:
NP-251 (repirinast), company’s lead candidate for the treatment of chronic kidney disease, binds to receptors on mast cell and prevents their degranulation. Repirinast originally developed by Mitsubishi was sold in Japan under the brand name Romet™ for the treatment of Asthma.
Lead Product(s): Repirinast
Therapeutic Area: Nephrology Product Name: NP-251
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2023
Details:
AP-188 (N,N-Dimethyltryptamine), is a tryptamine, non-selective agonist for 5HT2a receptor and produces hallucinogenic effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin. It is being investigated for ischemic stroke.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Neurology Product Name: AP-188
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2023
Details:
The capital raised will be used for research, development, and program management costs related to the completion of the Phase 1 DMT (N, N-dimethyltryptamine) study currently underway as well as Phase 2a stroke and traumatic brain injury (TBI) studies.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Neurology Product Name: DMT
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Dalmore Group
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 03, 2023
Details:
AP-188 (N,N-dimethyltryptamine) is a psychedelic tryptamine, non-selective agonist for 5HT2a receptor being developed as a therapy for patients with neurological & mental illness.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: AP-188
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2023
Details:
AP-188 (N,N-dimethyltryptamine) is a psychedelic tryptamine, non-selective agonist for 5HT2a receptor being developed as a therapy for patients with neurological & mental illness.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Neurology Product Name: AP-188
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2023
Details:
AP-188 (N,N-Dimethyltryptamine), is a tryptamine, non-selective agonist for 5HT2a receptor and produces hallucinogenic effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin. It is being investigated for ischemic stroke.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Neurology Product Name: AP-188
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2023
Details:
NP-120 (ifenprodil) selectively inhibits N-methyl-D-aspartate (NMDA) receptors containing the NR2B subunit. NMDA receptors are ion-channels found within the central and peripheral nervous system, including the area of the brain responsible for coordinating the cough reflex.
Lead Product(s): Ifenprodil Tartrate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: NP-120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023